PubMed Health⌕ Search

Biomedical subjects

L Ficker

Publications and source records attributed to L Ficker.

30 records · Page 2Linked to original sources
PubMed1990

Acanthamoeba keratitis--resistance to medical therapy.

Successful medical therapy of Acanthamoeba keratitis has been reported with combination therapy; topical Brolene and neomycin. Resistance has not so far been identified as a problem, but was the basis for recurrent disease observed in a patient with bilateral infection. Eradication of amoebae was finally achieved following prolonged topical therapy and two corneal grafts in each eye. Topical anti-amoebic therapy with paromomycin, benzethonium chloride, clotrimazole and R11/29 (a phenanthridinium compound), was continued for three months post-operatively. No further recurrences occurred during 14 months' follow-up. Drug sensitivities were performed for three isolates of Acanthamoeba sp (group II) which demonstrated the development of resistance to Brolene and arsenic. In addition, the resistant isolates were temperature-sensitive mutants which would not grow at temperatures above 30 degrees C. This could explain 'culture-negative' results in some cases of clinical recurrence when incubation of laboratory samples had only been performed at 37 degrees C.

Acanthamoeba Keratitis↗
PubMed1989

Staphylococcal infection and the limbus: study of the cell-mediated immune response.

The relationship between enhanced cell-mediated immunity (CMI) to staphylococcal antigens, expressed as delayed hypersensitivity (DH), and the development of catarrhal infiltrates at the limbus in the rabbit has been explored by others. This DH is required for infiltrates to develop in the rabbit cornea when it is exposed to conjunctival inoculation with live Staphylococcus aureus cells. Similar investigations have not been pursued in the human, although St. aureus has been isolated from lids of patients with sterile marginal ulcers. We have tested 69 patients with blepharitis, eleven with and 58 without associated symptomatic marginal keratitis, for DH to killed whole cells of St. aureus and St. epidermidis and protein A; quantitative cultures have also been collected from lids and conjunctivae. Preliminary findings show that nine out of 11 patients with symptomatic marginal keratitis, requiring treatment with steroids, have enhanced DH to St. aureus cell wall antigens. We suggest the hypothesis that this type of marginal keratitis in the human is the result of enhanced CMI at the limbus to St. aureus cell wall antigens.

Adult↗
PubMed1988

Suppression of experimental tractional retinal detachment by low-dose radiation therapy.

We used a standardized model of traction retinal detachment (TRD) created by cellular membranes in the rabbit to test the effects of low-dose radiation therapy in suppressing TRD. The vitreous and lens were removed from pigmented rabbits, and homologous conjunctival fibroblasts were grown in cell culture. After resolution of postoperative inflammation, 50,000 fibroblasts in 0.1 mL of culture fluid were injected into the vitreous cavity. Ten eyes were maintained as controls. Nineteen eyes received 6 Gy (600 rad) of x-ray irradiation one to three hours after cellular injection. Eyes were monitored weekly for three weeks with indirect ophthalmoscopy. Seven (70%) of ten control eyes developed TRD at one week; no additional TRDs were noted at weeks 2 and 3. Significantly smaller numbers of irradiated eyes developed TRD: at week 1, two (11%) of 19; at week 2, five (28%) of 18; and at week 3, five (29%) of 17.

Animals↗
PubMed1988

Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy.

In a prospective randomised trial of argon laser photocoagulation in the management of central serous retinopathy, long-term follow-up (6.4 to 12.1 years) revealed no evidence that treatment significantly influenced the visual outcome as measured by the Snellen chart and by the Farnsworth-Munsell 100-hue test. Treatment did not reduce either the recurrence rate or the prevalence of chronic disease. Complications of treatment were uncommon. The justification for argon laser photocoagulation appears to be limited to the hastening of symptomatic relief by earlier resolution of serous detachment.

Clinical Trials as Topic↗
PubMed1987

Chronic bacterial endophthalmitis.

We studied a specific syndrome of uveitis secondary to intraocular bacterial pathogens of low virulence after extracapsular cataract extraction and intraocular lens implantation in three eyes. The onset of photophobia, visual impairment, conjunctival redness, and uveitis was delayed for four days to 12 weeks after surgery. Chronic inflammation persisted for five weeks to 16 months before a definitive diagnosis was made. Signs and symptoms were suppressed by administration of topical and systemic corticosteroids. Intraocular biopsy and antibiotic injection both established the cause as bacterial endophthalmitis and resulted in resolution of signs and symptoms. Staphylococcus epidermidis was cultured in two eyes and Achromobacter was cultured in one.

Adrenal Cortex Hormones↗
PubMed1986

Infectious endophthalmitis.

A clinical series of twenty-eight cases of suspected infectious endophthalmitis was reviewed. The combination of epidemiology and peroperative microscopy at the time of vitreous biopsy provided a useful indication of the pathogen involved. The visual prognosis was related to the virulence of the pathogen, and to the delay between recognition of symptoms or signs and treatment. It appears possible to predict high risk groups which warrant a high index of clinical suspicion and prompt diagnosis to enable early vitrectomy with injection of appropriate intraocular antibiotics.

Endophthalmitis↗
PubMed1986

Longterm results of treatment of central serous retinopathy--a preliminary report.

The longterm follow-up of 38 patients with central serous retinopathy who were recruited into a prospective randomised trial of argon laser photocoagulation is reported. They were reviewed at a mean of 9.3 years after presentation. The results support the original findings that treatment shortens the disease, but does not benefit the final visual outcome.

Clinical Trials as Topic↗
PubMedDate not supplied

Cataract: current management.

Current management of cataract is aimed at assessing the impact of cataract on the quality of life and determining the role of surgical correction in the context of the expected surgical complications.

Aged↗